Jivan Launches Cancer Splice Variant Microarray

Berkeley, CA (December 9, 2004) -- Jivan Biologics, Inc., a privately held company, today announced the launch of TransExpress™ Cancer Splice Variant Microarray.

"TransExpress™ Cancer expands Jivan's product suite to benefit oncology researchers," said Subha Srinivasan, Ph.D., Jivan's Chief Executive. "In two SBIR grants from the NIH, Jivan has already demonstrated the applicability of splice variant profiling to find molecular signatures for cancer. With TransExpress™ Cancer, other research groups can explore this new and powerful approach."

TransExpress™ Cancer enables the profiling of 1,048 splice sites that have been empirically linked to common forms of cancer and corresponding normal samples by a leading academic research group. The microarray includes 524 pairs of oligonucleotides optimized for splice variant profiling. Each pair consists of a splice site specific to normal cells and an alternative splice site specific to tumor cells.

By enabling the profiling of splice variants in tumor and normal samples, TransExpress™ Cancer allows researchers to identify molecular signatures for cancer biology that could not otherwise be discovered. It uses splice variant specific probes, optimized using Jivan's patent-pending methods, to go beyond gene expression.

Jivan Biologics is a pioneer of high-throughput solutions to measure alternative splicing in vitro. Jivan Biologics' flagship TransExpress™ microarrays for alternative splicing provide pharmaceutical and biotechnology partners with greater precision and accuracy in disease profiling by comprehensively measuring the expression and changes in RNA splicing across entire protein families and pathways. For more information, please visit www.jivanbio.com.